{"nctId":"NCT01569295","briefTitle":"Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )","startDateStruct":{"date":"2012-06-15","type":"ACTUAL"},"conditions":["Chronic Lymphocytic Leukemia"],"count":416,"armGroups":[{"label":"Idelalisib+bendamustine+rituximab","type":"EXPERIMENTAL","interventionNames":["Drug: Idelalisib","Drug: Rituximab","Drug: Bendamustine"]},{"label":"Placebo to match idelalisib+bendamustine+rituximab","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Rituximab","Drug: Bendamustine","Drug: Placebo to match idelalisib"]}],"interventions":[{"name":"Idelalisib","otherNames":["GS-1101","CAL-101","Zydelig®"]},{"name":"Rituximab","otherNames":["Rituxan®","MabThera"]},{"name":"Bendamustine","otherNames":["Ribomustin","Treanda®"]},{"name":"Placebo to match idelalisib","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Previously treated recurrent CLL\n* Measurable lymphadenopathy\n* Requires therapy for CLL\n* Has experienced CLL progression \\< 36 months since the completion of the last prior therapy\n\nKey Exclusion Criteria:\n\n* Recent history of a major non-CLL malignancy\n* Evidence of an ongoing infection\n* CLL refractory to bendamustine\n* Concurrent participation in another therapeutic clinical trial\n\nNOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS)","description":"PFS was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause. PFS (months) = (minimum (date of disease progression, date of death) - date of randomization + 1)/30.4375.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","spread":null},{"groupId":"OG001","value":"11.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR)","description":"ORR was the percentage of participants who achieved a complete response (CR), CR with incomplete marrow recovery (CRi,) or partial response (PR) and maintained the response for at least 12 weeks. CR was defined as no lymphadenopathy, hepatomegaly, splenomegaly; normal complete blood count; confirmed by bone marrow aspirate \\& biopsy.\n\nPR was defined as \\>1 of the following criteria: a 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver size, spleen size; plus ≥ 1 of the following: ≥ 1500/μL absolute neutrophil count, \\> 100000/μL platelets, \\> 11.0 g/dL hemoglobin or 50% improvement for either of these parameters without transfusions or growth factors. CRi was defined as all criteria for CR met but with persistent anemia, thrombocytopenia, neutropenia or a hypocellular bone marrow.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","spread":null},{"groupId":"OG001","value":"45.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Lymph Node Response Rate","description":"Lymph node response rate was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.9","spread":null},{"groupId":"OG001","value":"60.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival (OS) was defined as the interval from randomization to death from any cause. Overall survival (months) = (date of death - date of randomization + 1)/30.4375.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.2","spread":null},{"groupId":"OG001","value":"42.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Response Rate","description":"Complete response (CR) rate was defined as the percentage of participants who achieved a CR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":152,"n":207},"commonTop":["Neutropenia","Diarrhoea","Pyrexia","Nausea","Anaemia"]}}}